

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden	
hours per response:	0.5

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP**

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>AISLING CAPITAL III LP</u> <hr/> (Last) (First) (Middle) 888 Seventh Avenue, 30th Fl <hr/> (Street) New York NY 10106 <hr/> (City) (State) (Zip)			2. Issuer Name and Ticker or Trading Symbol <u>T2 Biosystems, Inc. [ TTOO ]</u>			5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) Other (specify below)		
			3. Date of Earliest Transaction (Month/Day/Year) 08/12/2014			6. Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person <input checked="" type="checkbox"/> Form filed by More than One Reporting Person		
			4. If Amendment, Date of Original Filed (Month/Day/Year)					

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	08/12/2014		C		2,068,755	A	\$0 <sup>(1)</sup>	2,068,755	I	See footnote <sup>(2)</sup>
Common Stock	08/12/2014		P		454,545	A	\$11	2,523,300	I	See footnote <sup>(2)</sup>

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Series D Convertible Preferred Stock	\$0 <sup>(1)</sup>	08/12/2014		C			2,967,033	(1)	(1)	Common Stock	1,745,313	\$0 <sup>(1)</sup>	0	I	See footnote <sup>(2)</sup>
Series E Convertible Preferred Stock	\$0 <sup>(1)</sup>	08/12/2014		C			549,851	(1)	(1)	Common Stock	323,441	\$0 <sup>(1)</sup>	0	I	See footnote <sup>(2)</sup>

1. Name and Address of Reporting Person\*  
AISLING CAPITAL III LP  


---

 (Last) (First) (Middle)  
 888 Seventh Avenue, 30th Fl  


---

 (Street)  
 New York NY 10106  


---

 (City) (State) (Zip)

1. Name and Address of Reporting Person\*  
Aisling Capital Partners III LLC  


---

 (Last) (First) (Middle)  
 AISLING CAPITAL LLC  
 888 SEVENTH AVENUE 30TH FLOOR  


---

 (Street)  
 NEW YORK NY 10106  


---

 (City) (State) (Zip)

1. Name and Address of Reporting Person\*  
Aisling Capital Partners III LP  


---

 (Last) (First) (Middle)

AISSLING CAPITAL LLC  
888 SEVENTH AVENUE 30TH FLOOR

(Street)  
NEW YORK NY 10106

(City) (State) (Zip)

1. Name and Address of Reporting Person\*

SCHIFF ANDREW N

(Last) (First) (Middle)

PLANET ZANETT INC  
135 E 57TH ST

(Street)  
NEW YORK NY 10022

(City) (State) (Zip)

1. Name and Address of Reporting Person\*

Purcell Dennis J

(Last) (First) (Middle)

AUXILIUM PHARMACEUTICALS, INC.  
160 WEST GERMANTOWN PIKE

(Street)  
NORRISTOWN PA 19401

(City) (State) (Zip)

1. Name and Address of Reporting Person\*

ELMS STEVE

(Last) (First) (Middle)

888 SEVENTH AVE  
29TH FL

(Street)  
NEW YORK NY 10106

(City) (State) (Zip)

Explanation of Responses:

1. The preferred stock is convertible at any time, at the holder's election and has no expiration date. The preferred stock automatically converted into common stock upon the closing of the Issuer's initial public offering.
2. The reportable securities are owned directly by Aisling Capital III, LP ("Aisling"), and held indirectly by Aisling Capital Partners III, LP ("Aisling GP"), as general partner of Aisling, Aisling Capital Partners III LLC ("Aisling Partners"), as general partner of Aisling GP, and each of the individual managing members of Aisling Partners. The individual managing members (collectively, the "Managers") of Aisling Partners are Dennis Purcell, Dr. Andrew Schiff and Steve Elms. Aisling GP, Aisling Partners and the Managers share voting and dispositive power over the shares directly held by Aisling.

AISSLING CAPITAL III, L.P.  
By: Aisling Capital Partners III,  
L.P., its General Partner, By: 08/14/2014  
Aisling Capital Partners III,  
LLC, its General Partner, By: /s/  
Lloyd Appel, CFO  
AISSLING CAPITAL  
PARTNERS III, L.P. By: Aisling  
Capital Partners III, LLC, its 08/14/2014  
General Partner, By: /s/ Lloyd  
Appel, CFO  
AISSLING CAPITAL  
PARTNERS III, LLC By: /s/ 08/14/2014  
Lloyd Appel, CFO  
/s/ Andrew Schiff 08/14/2014  
/s/ Dennis Purcell 08/14/2014  
/s/ Steve Elms 08/14/2014

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.